## SRPT: Sarepta Therapeutics, Inc. - XLV: Healthcare

### Executive Summary

STRENGTH thesis confirmed: MRS_20 at 7.2% in mid entry zone (4.0-10.0%), top quartile (87th pct) cross-sectional ranking. Caution: MRS_5 (-1.4%) diverging from MRS_20, watch for reversal. Outperforming sector by 9.5%. Caution: momentum weakening (-7.2% MRS).

- **Horizon:** 5-20 days (swing)
- **Risk Profile:** Moderate - momentum continuation
- **Stop Type:** Fixed 2xATR ($18.93)
- **If Wrong:** Exit if MRS_20 drops below entry zone or breaks stop
- **Invalidation:** MRS_20 exits entry zone or MRS_5 turns negative

### News

- **Articles:** 9
- **Sentiment:** Bullish (Bullish: 3, Bearish: 0)

**1. Sarepta a new outperform at Wedbush as selloff overdone**
- Source: Seeking Alpha | 20251209T160905 | Bullish | Relevance: 99%
- Wedbush initiated coverage on Sarepta Therapeutics (SRPT) with an Outperform rating. The firm believes the selloff, which occurred earlier this year following the deaths of two boys on one of its Duchenne muscular dystrophy gene therapies, is overdone. Wedbush has set a $32 price target for SRPT.

**2. Sarepta to refinance $291M of existing notes due 2027**
- Source: MSN | 20251211T131006 | Somewhat-Bullish | Relevance: 99%
- Sarepta Therapeutics plans to refinance $291 million of its existing 1.125% convertible senior notes due in 2027 by offering new convertible senior notes due in 2029. The refinancing aims to manage its debt structure and financial obligations related to these securities.

**3. Sarepta Therapeutics (SRPT): Reassessing Valuation After a Sharp One-Month Share Price Rebound**
- Source: Yahoo Finance | 20251210T050840 | Neutral | Relevance: 98%
- Sarepta Therapeutics (SRPT) has seen a significant 28.37% share price rebound over the last month, yet its one-year return remains deeply negative. Analysts have a consensus price target of $23.96, suggesting a slight overvaluation at its current price of $22.17 after accounting for future earnings and risk factors. However, the stock trades at a much lower price-to-sales ratio compared to its industry and peers, potentially indicating that a market recovery in sentiment is not yet fully reflected in its valuation.

**4. Sarepta Therapeutics (SRPT) Is Up 6.8% After FDA Clears Cohort 8 Dosing in ENDEAVOR Trial**
- Source: Simply Wall Street | 20251209T100905 | Neutral | Relevance: 98%
-  Sarepta Therapeutics saw a 6.8% stock increase after the FDA approved dosing in Cohort 8 of its ENDEAVOR trial for ELEVIDYS in non-ambulant Duchenne muscular dystrophy patients. This regulatory step is crucial for expanding ELEVIDYS's use beyond ambulant patients while managing safety concerns like liver injury. The company faces an investment narrative challenged by these safety concerns, impacting uptake and revenue timing, but the Cohort 8 approval offers a positive direction for label expansion efforts.

**5. Sarepta Therapeutics stock falls after debt exchange announcement**
- Source: Investing.com | 20251211T151006 | Neutral | Relevance: 98%
-  Sarepta Therapeutics stock dropped 3.7% after the company announced a debt exchange agreement. This deal involves restructuring approximately $291.4 million of its 1.25% convertible senior notes due 2027 into new 4.875% convertible senior notes due 2030, plus a cash component. The transaction is expected to finalize on December 18th.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 0, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-09 | Wedbush | $32 | $0 | 0% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-09 | Wedbush | init | Outperform |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 0 ($0.00M) |
| Sells | 2 ($0.09M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 106.5% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 8 / 2 |

**Top Holders:**
- Tudor Investment Cor: 65.7% (+135261.8%)
- Blackrock Inc.: 12.6% (+8.9%)
- Vanguard Group Inc: 10.3% (+18.1%)
- State Street Corpora: 5.1% (+13.0%)
- Erste Asset Manageme: 2.6% (+65.7%)

### Key Risks

1. Valuation stretched: PEG 159.2x requires aggressive growth execution.
2. High short interest (21.6%, 3.4 days to cover): squeeze risk or crowded bearish bet.
3. Long-term trend broken: trading 37.1% below SMA200.
4. Falling knife pattern: rapid decline without stabilization, catch risk elevated.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

PEG ratio 159.25 signals overvaluation risk, limited margin of safety. Balance sheet: strong liquidity (3.0x). Revenue declining -25% YoY, concerning. Institutional flow bullish (8 buying vs 2 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $2.3B |
| Beta | 0.53 |
| 52W Range | $10.42 - $129.84 |
| Short Interest | 21.6% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 159.25 |
| Forward P/E | 7.5 |
| Current P/E | N/A |
| YoY Growth | N/A |
| EPS Direction | None |

### Technicals

MRS_20 deteriorating from 14.4% to 7.2% (-7.2% in 5 days), indicating relative weakness vs NASDAQ. Currently in upper STRENGTH zone (4.0-10.0%), cross-sectional ranking at 87th percentile. MRS_5 (-1.4%) diverging from MRS_20 - short-term weakness emerging. AM_20 at 9.3% shows strong absolute momentum above own 20MA. Outperforming sector by 9.5pp, stock-specific strength. Below SMA200 (0.63x), long-term trend not supportive. RSI neutral at 56.

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | 7.21% (CS: 87) | Strong |
| RSI_14 | 55.8 | Neutral |
| MACD Histogram | 0.34 | Bullish |
| vs SMA20 | 1.093x | Above |
| vs SMA50 | 1.037x | Above |
| vs SMA200 | 0.629x | Below |

### Decision

- **Verdict:** AVOID
- **Thesis:** STRENGTH

### Trade Setup

- **Entry:** $21.75
- **Stop Loss:** $18.93 (13.0% risk)
- **Target:** $25.98 (R:R method)
- **Risk/Reward:** 1.50:1
- **Target Reasoning:** STRENGTH thesis targets 1.5x risk/reward based on historical edge

### Position Sizing

- **Shares:** 489
- **Position Value:** $10,635.75
- **Portfolio %:** 10.64%
- **Risk Dollars:** $1,380.00
- **Risk Per Trade:** 1.38%
- **Modifiers:** L1 115% | L2 120% | Combined 1.38x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.15x |
| L2 Sector | IGNITION (Zone D) | 1.20x |

*NORMAL regime with moderate risk appetite ahead of Fed decision. VIX at low 8th percentile signals complacency, but decent breadth and positive yield curve support selective positioning. Focus on quality names with earnings visibility.*

### Earnings

**Next:** 2026-02-25 (Est: $-0.71)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $-0.37 | $-0.13 | +65.0% |
| 2025Q2 | $1.16 | $2.02 | +73.9% |
| 2025Q1 | $-0.65 | $-3.42 | -426.6% |
| 2024Q4 | $2.06 | $1.90 | -7.8% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_20*